In This Article:
Over the last 7 days, the United States market has dropped 2.7%, but it has shown resilience with an 11% rise over the past year and earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive longer-term trends.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 26.19% | 37.78% | ★★★★★★ |
| Alkami Technology | 21.98% | 85.17% | ★★★★★★ |
| Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
| AVITA Medical | 27.78% | 55.33% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.90% | 58.64% | ★★★★★★ |
| Applied Optoelectronics | 58.93% | 141.15% | ★★★★★★ |
| Alvotech | 31.17% | 100.18% | ★★★★★★ |
| Blueprint Medicines | 22.38% | 55.75% | ★★★★★★ |
| Lumentum Holdings | 21.24% | 119.37% | ★★★★★★ |
Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Vertex
Simply Wall St Growth Rating: ★★★★★☆
Overview: Vertex, Inc. offers enterprise tax technology solutions for the retail trade, wholesale trade, and manufacturing industries both in the United States and internationally, with a market cap of approximately $5.39 billion.
Operations: Vertex, Inc. generates revenue primarily from its Software & Programming segment, which contributes approximately $666.78 million. The company focuses on providing tax technology solutions across retail trade, wholesale trade, and manufacturing sectors globally.
Vertex's trajectory in the high-growth tech sector is underscored by a robust forecast of 96.2% annual earnings growth and a projected revenue increase of 12.6% per year, outpacing the US market average of 8.5%. Despite current unprofitability, the firm is expected to shift into profitability within three years, reflecting its potential resilience and adaptability in a competitive landscape. Recent enhancements to their Vertex e-invoicing solution illustrate their commitment to innovation, addressing global complexities in tax regulation which could significantly streamline client operations worldwide. This strategic focus on scalable tech solutions not only meets increasing digital demands but also positions Vertex favorably for future industry requirements and growth.
-
Unlock comprehensive insights into our analysis of Vertex stock in this health report.
-
Understand Vertex's track record by examining our Past report.
Anavex Life Sciences
Simply Wall St Growth Rating: ★★★★★☆
Overview: Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases in the United States, with a market cap of $742.61 million.